Reuters: Aethlon Medical Inc said the U.S. Food and Drug Administration approved testing of the company's experimental device in Ebola patients.
Patients will be administered for six to eight hours daily with the company's device, Hemopurifier, until the Ebola viral load drops below 1000 copies/ml, Aethlon said on Friday.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now